Diplomat Named a Preferred Specialty Pharmacy Vendor by the Association for Community Affiliated Plans (ACAP)
FLINT, Mich. – June 12, 2015 – Diplomat’s clinical excellence and emphasis on patient education aligns with ACAP’s efforts to support Medicaid-focused health plans.
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it has been designated as a Preferred Specialty Pharmacy Vendor from the Association for Community Affiliated Plans (ACAP).
ACAP is a national trade association representing 59 not-for-profit Safety Net Health Plans in 24 states. Collectively, ACAP plans serve 13 million lives in Medicaid, Medicare, CHIP and other public programs.
In the ACAP Preferred Vendor Program, pre-qualified organizations are granted access to specific areas of interest for ACAP plans and their members. Each vendor must be approved by the ACAP board.
“We are honored to be named a Preferred Vendor to ACAP,” said Atheer Kaddis, Senior Vice President, Sales and Business Development at Diplomat. “Our focus on education, adherence efforts and helping manage costs of our patients make Diplomat an ideal fit for ACAP’s plans and the individuals they serve.”
As a Preferred Vendor in the area of specialty pharmacy services, Diplomat offers its expertise to help meet the needs of ACAP plans as they strive to improve the health and well-being of lower-income and vulnerable populations.
To learn more about Diplomat, visit www.diplomat.is.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance, and include the Company’s expectations regarding future tax benefits, and the financial and operational performance of the combined entities. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information, and these statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. These risks and uncertainties include: delays or difficulties in integrating the combined businesses; general economic conditions in the regions and industries in which the parties operate; and the ability to achieve cost savings and operating synergies and the timing thereof. The foregoing transaction risks should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included herein and elsewhere, including in “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2014 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
Kali Lucas, Public Relations Coordinator
810.768.9580 | email@example.com
Atheer Kaddis, Senior Vice President, Sales and Business Development
810.768.9519 | AKaddis@diplomat.is
@Pharmacy_TimesRT @Pharmacy_Times: .@US_FDA Officials OK Tofacitinib for Active Psoriatic #Arthritis https://t.co/vE6PT5Vl6d1 day ago
@FDA_Drug_InfoRT @FDA_Drug_Info: FDA approves first drug for Eosinophilic Granulomatosis with Polyangiitis, a rare disease formerly known as the Churg-St…2 days ago
@SpecialtyPTimesRT @SpecialtyPTimes: PBM Acquisition Allows @DiplomatRx to Expand Patient-Centric Offerings https://t.co/ntV4kEsnvX4 days ago
@DiplomatRxDiplomat Adds Chris Luthin as Executive Vice President https://t.co/JI0e9UIBHe5 days ago
@DiplomatRxDon’t forget to register for @CBI_Conferences “Patient Journey Mapping—From Diagnosis to Treatment.” This event gat… https://t.co/czVklVOW6Z5 days ago